Roquefort Therapeutics plc

LSE ROQ.L

Roquefort Therapeutics plc Operating Income Margin for the year ending December 31, 2023: -966.82%

Roquefort Therapeutics plc Operating Income Margin is -966.82% for the year ending December 31, 2023. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.
  • Roquefort Therapeutics plc Operating Income Margin for the year ending December 31, 2021 was -71,038.80%.
Key data
Date Operating Income Margin EBT Margin Net Income Margin EBITDA Margin
Market news
SV Wall Street
LSE: ROQ.L

Roquefort Therapeutics plc

CEO Mr. Trevor Ajanthan Reginald
IPO Date March 22, 2021
Location United Kingdom
Headquarters Eccleston Yards
Employees 10
Sector Healthcare
Industries
Biotechnology Clinical Trials Pharmaceuticals Vaccines Venture Capital
Description

Roquefort Therapeutics plc operates as a biotechnology research company. The company engages in the research and development of drugs targeting Midkine, a circulating growth factor protein and pro-inflammatory mediator for the treatment of cancer. Roquefort Therapeutics plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

StockViz Staff

February 5, 2025

Any question? Send us an email